Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.76 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.76 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22119593 | 1.00 | CRBN (0.76) | CRBNDDB1CHEK1PDGFRACDK5 | |
| SCHEMBL29946918 | 0.98 | CRBN (0.72) | CRBNDDB1CHEK1PDGFRACDK5 | |
| SCHEMBL24816843 | 0.90 | CRBN (0.69) | CRBNDDB1TNKSTNKS2 | |
| SCHEMBL26621484 | 0.86 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL23551579 | 0.86 | CRBN (0.77) | CRBNDDB1 | |
| SCHEMBL24126163 | 0.85 | CRBN (0.76) | CRBNDDB1 | |
| SCHEMBL31731820 | 0.84 | CRBN (0.71) | CRBNDDB1TNKSTNKS2 | |
| SCHEMBL25122073 | 0.83 | CRBN (0.72) | CRBNDDB1 | |
| SCHEMBL30774975 | 0.83 | CRBN (0.72) | CRBNDDB1 | |
| SCHEMBL25594932 | 0.83 | CRBN (0.72) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146050-A1 | KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-05-28 | — | — | US | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4722209-A1 | PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Shenogen Pharma Group (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2023055952-A1 | NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) DEGRADING COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023025091-A1 | HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283372-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022251539-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4076450-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146050-A1 | KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES | KRAS, NRAS, HRAS | CRBN 206/4885DDB1 436/4885CHEK1 39/4885 |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | CRBN 429/4885DDB1 308/4885CHEK1 155/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | CRBN 277/4885DDB1 270/4885CHEK1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.